🇺🇸 Qiliqiangxin Capsule in United States
5 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 5
Most-reported reactions
- Brain Contusion — 1 report (20%)
- Brain Injury — 1 report (20%)
- Craniocerebral Injury — 1 report (20%)
- Glomerulonephritis Chronic — 1 report (20%)
- Subarachnoid Haemorrhage — 1 report (20%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Qiliqiangxin Capsule approved in United States?
Qiliqiangxin Capsule does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Qiliqiangxin Capsule in United States?
Harbin Medical University is the originator. The local marketing authorisation holder may differ — check the official source linked above.